FDA Cracks Down On Unregistered Foreign Pharmaceutical Manufacturers
This article was originally published in The Pink Sheet Daily
The agency has sent 11 warning letters for failure to register and list as importers of drugs into the U.S. since the beginning of the year.
You may also be interested in...
An FDA draft guidance defines which generic drug manufacturers and other entities must self-report under the new user fee law and which must pay facility fees. It also outlines practical steps companies should take now to meet requirements by deadline.
The user fee legislation Congress approved June 26 makes quality risk management a GMP requirement, further pressuring pharmaceutical manufacturers to make sure they are protecting their global supply chains. The bill directs FDA to inspect based on risk rather than time or location, and to rely on trusted foreign inspectorates, while adding new user fees for generic drugs that will boost funding for further expansion of the agency’s inspectorate.